Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase |
| |
Authors: | Zhen-Dan Shi Omid Motabar Ehud Goldin Ke Liu Noel Southall Ellen Sidransky Christopher P. Austin Gary L. Griffiths Wei Zheng |
| |
Affiliation: | (1) NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892-3370, USA;(2) Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3708, USA;(3) Imaging Probe Development Center, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-3708, USA |
| |
Abstract: | Alpha-galactosidase A hydrolyzes the terminal alpha-galactosyl moieties from glycolipids and glycoproteins in lysosomes. Mutations in α-galactosidase cause lysosomal accumulation of the glycosphingolipid, globotriaosylceramide, which leads to Fabry disease. Small-molecule chaperones that bind to mutant enzyme proteins and correct their misfolding and mistrafficking have emerged as a potential therapy for Fabry disease. We have synthesized a red fluorogenic substrate, resorufinyl α-d-galactopyranoside, for a new α-galactosidase enzyme assay. This assay can be measured continuously at lower pH values, without the addition of a stop solution, due to the relatively low pK a of resorufin (~6). In addition, the assay emits red fluorescence, which can significantly reduce interferences due to compound fluorescence and dust/lint as compared to blue fluorescence. Therefore, this new red fluorogenic substrate and the resulting enzyme assay can be used in high-throughput screening to identify small-molecule chaperones for Fabry disease. Zhen-Dan Shi and Omid Motabar contributed equally to this work |
| |
Keywords: | Alpha-galactosidase Enzyme assay Assay optimization Assay miniaturization Fabry disease |
本文献已被 SpringerLink 等数据库收录! |
|